Connect

Partner News

Partner News

DHHS Funding Opportunities

FUNDING OPPORTUNITIES from the Department of Health and Human Services (DHHS)

________________________________________________________________________

Department of Health and Human Services – National Institutes of Health – Emergency Award: RADx-UP – Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trials Optional)

Proposal Due Date: July 7, 2021

Expected Number of Awards: 16

Estimated Total Program Funding: $24,000,000

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-OD-21-009

Purpose: High rates and disparities of COVID-19 infection, morbidity, and mortality continue among underserved and vulnerable populations across the United States. The overarching goal of the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative is to understand and ameliorate factors that have placed a disproportionate burden of the pandemic on underserved and/or vulnerable populations, specifically by implementing programs that expand the scope and reach of COVID-19 testing interventions to reduce these disparities. To address barriers to testing and vaccination, social, ethical, and behavioral research is urgently needed to inform related mitigation efforts. This Phase II RADx-UP Funding Opportunity Announcement (FOA) is designed to expand research to understand and address the social, ethical, and behavioral implications (SEBI) of COVID-19 testing interventions among underserved and vulnerable populations. Desirable studies for Phase II will move beyond descriptive health disparities research to focus on developing interventions and other actionable solutions in collaboration with community partners and stakeholders. The funding for this initiative is provided from the American Rescue Plan Act of 2021.

https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-21-009.html?utm_medium=email&utm_source=govdelivery&utm_source=sfmc&utm_medium=email&utm_campaign=HER&utm_content=newsletter

Department of Health and Human Services – National Institutes of Health – Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations – RADx-UP Phase II (U01 Clinical Trial Optional)

Proposal Due Date: July 7, 2021

Expected Number of Awards: 25 to 50

Estimated Total Program Funding: $100,000,000

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-OD-21-008

Purpose: 

https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-21-008.html?utm_medium=email&utm_source=govdelivery&utm_source=sfmc&utm_medium=email&utm_campaign=HER&utm_content=newsletter

Department of Health and Human Services – Centers for Disease Control – CGH – Technical Collaboration to Strengthen Bangkok Metropolitan Administration Capacity to Detect, Prevent, Respond, Monitor, and Mitigate The Effects of Public Health Threats In The Kingdom of Thailand

Proposal Due Date: July 5, 2021

Expected Number of Awards: 1

Estimated Total Program Funding: $1,000,000

Award Ceiling: $1,000,000

Award Floor: $0

Funding Opportunity Number: CDC-RFA-GH21-2107

Purpose: CDC is working through strong partnerships with governing bodies around the world to assure that implementation and evaluation of public health programs increases public health impact and that the knowledge gained can be accessed and applied in other settings.

The BMA governs and manages public health services within Bangkok, Thailand and its surrounding urban areas. This NOFO will complement efforts by BMA and its national and international partners to prevent, monitor, assess, and mitigate public health threats in the Bangkok Metropolitan area. It will do this through (a) assessment of existing health behaviors, health care services and systems in Bangkok; (b) design, development, and implementation of standard procedures and practices for high-quality services by BMA health facilities and laboratories; and (c) capacity building and mentorship of BMA health care workers, laboratory staff, strategic information (SI) experts, and program managers to implement, monitor, and continuously improve the quality of those procedures and practices so as to enhance prevention, detection, response, and preparation for public health threats. Achieving those goals in Bangkok requires a multifaceted approach that embraces all partners.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333360

Department of Health and Human Services – Centers for Disease Control – CGH – Technical Collaboration to Strengthen and Expand Capacity to Detect, Prevent, Respond and Mitigate the Effects of Public Health Threats of National and Global Importance with the Ministry of Public Health (MoPH) in the Kingdom of Thailand

Proposal Due Date: July 4, 2021

Expected Number of Awards: 1

Estimated Total Program Funding: $47,500,000

Award Ceiling: $9,500,000

Award Floor: $0

Funding Opportunity Number: CDC-RFA-GH21-2106

Purpose: CDC is working through its strong partnerships to increase global health impact and assure the implementation and evaluation of public health programs will result in the prevention and control of diseases and subsequently apply the knowledge gained to other settings. The Thailand MoPH is the key stakeholder to enable CDC to execute its global health strategies and other public health priorities in Thailand and the Southeast Asia region. Over the past several years, a variety of public health approaches implemented by CDC and Thailand MoPH have successfully prevented new infections, improved care and treatment of existing diseases, and strengthened the capacity to collect and use surveillance data.

Despite advances, major challenges still persist. Over the past four decades, Thailand has undergone significant social, economic, and demographic changes. Demographic changes have resulted in an increasingly aging population structure, as well as increased exposure to non-communicable disease (NCD) risk factors, such as poor diet, sedentary lifestyle, tobacco consumption and harmful use of alcohol. The top three causes of deaths (cardiovascular disease (CVD), cancer, and injury) in Thailand are all NCDs. Infectious diseases continue to be serious public health issues impacting Thailand and the Mekong region-extending globally as more people travel. Overall HIV incidence has decreased, but incidence and prevalence remain high among key populations, particularly men who have sex with men (MSM) and transgender (TG) women and sex workers in larger urban areas.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333316

Department of Health and Human Services – Centers for Disease Control – NCCDPHP – Closing the Gap with Social Determinants of Health Accelerator Plans

Proposal Due Date: July 6, 2021

Expected Number of Awards: 20

Estimated Total Program Funding: $2,500,000

Award Ceiling: $125,000

Award Floor:

Funding Opportunity Number: CDC-RFA-DP21-2111

Purpose: To maximize public health impact, policy, systems, environmental, programmatic, and

infrastructure strategies and activities that address SDOH have the potential to narrow disparities

in many chronic diseases by removing systemic and unfair barriers to practicing healthy

behaviors. Sustaining positive health outcomes requires a focus not just on individual behaviors

and patient care, but on root causes of disparities and community-wide approaches aimed at

improving population health. Healthy People 2030 categorizes SDOH into five domains: 1)

Economic Stability; 2) Education Access and Quality; 3) Health Care Access and Quality; 4)

Neighborhood and Built Environment; and 5) Social and Community Context.

Starting with the five domains of Healthy People 2030, CDC’s National Center for Chronic

Disease Prevention and Health Promotion has developed an integrated framework to addressing

SDOH (https://www.cdc.gov/chronicdisease/programs-impact/sdoh.htm) with significant

potential to impact health outcomes related to chronic disease. The five (5) priority areas include:

1) Built Environment

2) Community-Clinical Linkages

3) Food and Nutrition Security

4) Social Connectedness

5) Tobacco-Free Policy

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331686

Department of Health and Human Services – Centers for Disease Control – CSELS – CDC’s Collaboration with Academia to Strengthen Public Health Workforce Capacity

Proposal Due Date: July 6, 2021

Expected Number of Awards: 3

Estimated Total Program Funding:

Award Ceiling: $2,000,000

Award Floor: $300,000

Funding Opportunity Number: CDC-RFA-OE17-17010502SUPP21

Purpose: Project 1 Title: Public Health Emergency Preparedness and Response Applied Research and Practice Training Program Strategic Priority Area(s): Increase the capability of the existing workforce, strengthen systems and capacity to support the workforce.

Requested Budget: $400,000

Project 2 Title: Building COVID-19 Vaccine Confidence Among Nurses

Strategic Priority Area(s): 1. Enhance the education system, 2. Strengthen systems and capacity to support the workforce.

Project 3 Title: Public Health Data Modernization Workshop

Priority Area: Increase the capability of the existing workforce

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333156

Department of Health and Human Services – Food and Drug Administration – Pediatric and Perinatal COVID-19 Registry (U18) Clinical Trials Optional

Proposal Due Date: July 6, 2021

Expected Number of Awards: 1

Estimated Total Program Funding:

Award Ceiling: $2,000,000

Award Floor: $1,000,000

Funding Opportunity Number: RFA-FD-21-035

Purpose: The goal of this program is to support the development of a compendium-type resource incorporating pediatric and perinatal COVID-19 registries, natural history, and other data to support the linkage of mother-infant pair data in COVID-19 positive mothers and to identify the short and longer-term outcomes in neonates and infants who are perinatally exposed to and/or test positive for SARS CoV-2.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333252

Department of Health and Human Services – Food and Drug Administration – Integrated Pathogen Reduction Technologies for whole blood and blood components for transfusion (R01) Clinical Trials Not Allowed

Proposal Due Date: July 6, 2021

Expected Number of Awards: 5

Estimated Total Program Funding: $8,000,000

Award Ceiling: $4,000,000

Award Floor: $0

Funding Opportunity Number: RFA-FD-21-032

Purpose: CBER, FDA seeks to support the development of innovative pathogen reduction technologies for whole blood and blood components to prevent transfusion-transmitted infectious diseases.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333311

Department of Health and Human Services – Health Resources and Services Administration – Community-Based Workforce For COVID-19 Vaccine Outreach

Proposal Due Date: May 18, 2021

Expected Number of Awards: 10

Estimated Total Program Funding: $125,000,000

Award Ceiling:

Award Floor:

Funding Opportunity Number: HRSA-21-136

Purpose: The purpose of the program is to establish, expand, and sustain a public health workforce to prevent, prepare for, and respond to COVID-19. This includes mobilizing community outreach workers, which includes community health workers, patient navigators, and social support specialists, to educate and assist individuals in accessing and receiving COVID-19 vaccinations. This includes activities such as conducting face-to-face outreach and reaching out directly to community members to educate them about the vaccine, assisting individuals in making a vaccine appointment, providing resources to find convenient vaccine locations, assisting individuals with transportation or other needs to get to a vaccination site. The program intends to address persistent health disparities by offering support and resources to vulnerable and medically underserved communities, including racial and ethnic minority groups and individuals living in areas of high social vulnerability.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333305

Department of Health and Human Services – Health Resources and Services Administration – Children’s Hospitals Graduate and Medical Education

Proposal Due Date: July 15, 2021

Expected Number of Awards: 62

Estimated Total Program Funding: $323,000,000

Award Ceiling:

Award Floor:

Funding Opportunity Number: HRSA-22-051

Purpose: The purpose of this program is to fund freestanding children’s hospitals to support the training of pediatric and other residents in graduate medical education (GME) programs. This program addresses the difference in federal GME funding between freestanding children’s teaching hospitals and other teaching hospitals supported by the Centers for Medicare and Medicaid Services (CMS). 

The CHGME Payment Program supports the three-pronged missions of freestanding children’s teaching hospitals to:

 Funding children’s hospitals is at the core of Health Resources and Services Administration’s (HRSA) mission of strengthening the health workforce and connecting skilled professionals to communities in need.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333163

Department of Health and Human Services – National Institutes of Health – NeuroNEXT Clinical Trials (U01 Clinical Trial Optional)

Proposal Due Date: June 5, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling: $499,999

Award Floor:

Funding Opportunity Number: PAR-21-223

Purpose: This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies.  Diseases chosen for study should be based on the NINDS’ strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure.  The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study.  The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support.  The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. Applicants do not need to be part of the existing NeuroNEXT infrastructure.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333351

Department of Health and Human Services – National Institutes of Health – Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: June 5, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling: $499,999

Award Floor:

Funding Opportunity Number: PAR-21-229

Purpose: Rapid advances in genotyping and next generation sequencing technologies have led to the identification of genetic variants that are associated with a wide variety of congenital defects including structural birth defects (SBDs), intellectual developmental disabilities (IDDs) and inborn errors of metabolism (IEMs). Large quantities of genomic data collected from pediatric birth defects cohorts are available to the research community through several databases such as the Database of Genotypes and Phenotypes (dbGaP), the Gabriella Miller Kids First Data Resource Portal, the European Genome-Phenome Archive and Clinical Genome Resource (ClinGen). The purpose of this initiative is to promote the screening, functional validation and characterization of birth defects-associated genetic variants identified through public facing databases and individual efforts using in-silico tools, appropriate animal models, in vitro systems or multi-pronged approaches. This initiative addresses a challenging gap between identifying sequence variations of potential interest and recognizing which of those variations have functional effects on the phenotype of interest.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333357

Department of Health and Human Services – National Institutes of Health – NINDS Exploratory Clinical Trials (U01 – Clinical Trial Required)

Proposal Due Date: June 5, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-236

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (https://www.ninds.nih.gov/).

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333409

Department of Health and Human Services – National Institutes of Health – Research Program Award (R35 Clinical Trial Optional)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: June 13, 2021

Expected Number of Awards: 30

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-NS-21-020

Purpose: The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support and increased freedom and flexibility to Program Directors (PDs)/Principal Investigators (PIs) to allow them to redirect their time away from the administrative burden of writing and managing multiple grant applications and towards engaging in the lab. This RPA affords investigators at most career stages the opportunity to advance their long-term research goals, rigorously explore exciting research opportunities, and mentor trainees, which support and align with the mission of NINDS. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PIs recent NINDS support (Part 2, Section II). This greater funding stability will provide eligible investigators increased security, allowing them to undertake research projects that require a longer timeframe or to embark upon research that breaks new ground. Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center, will not be considered through this program.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333323

Department of Health and Human Services – National Institutes of Health – NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)

Proposal Due Date: June 16, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-235

Purpose: Reissue of PA-18-350. The NIMH Exploratory/Developmental Grant program supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. The preliminary work from these studies could lead to a major impact on biomedical, behavioral, or clinical mental health research, or on the delivery of mental health care.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333420

Department of Health and Human Services – National Institutes of Health – Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional) Proposal Due Date: June 16, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling: $200,000

Award Floor:

Funding Opportunity Number: RFA-NS-21-020

Purpose: The Joint NINDS/NIMH Exploratory Neuroscience Research Grant program supports exploratory and innovative research projects, which fall within the missions of the NINDS and NIMH. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community. While this funding opportunity also accepts clinical trials, only applications proposing “mechanistic clinical trials or studies” (studying pathophysiology or mechanism of action of an intervention, but not safety or efficacy) or basic experimental studies with humans (BESH) will be supported. For information on NIH clinical trial definitions and the types of clinical trials that are within scope of this funding opportunity announcement refer to the NIH Definition of a Clinical Trial page and the Funding Opportunity Description, below, respectively.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333445

Department of Health and Human Services – National Institutes of Health – BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional)

Letter of Intent Due Date: 60 days prior to application due date

Proposal Due Date: July 1, 2021

Expected Number of Awards:

Estimated Total Program Funding: $10,000,000

Award Ceiling: $1,000,000

Award Floor:

Funding Opportunity Number: RFA-NS-21-023

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and small clinical studies for recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study, as well as a subsequent small clinical study. Only Significant Risk (SR) clinical studies that will require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants, will be supported by this FOA. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.

Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to RFA-NS-21-024 or this FOA.

The BRAIN PPP includes agreements with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general, it is expected that the devices’ existing safety and utility data will be sufficient to enable new FDA IDE and IRB approvals without need for significant additional non-clinical data. For more information on the BRAIN PPP, see https://braininitiative.nih.gov/brain-programs/public-private-partnerships.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333402

Department of Health and Human Services – National Institutes of Health – BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional) Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: July 1, 2021

Expected Number of Awards:

Estimated Total Program Funding: $10,000,000

Award Ceiling: $1,500,000

Award Floor:

Funding Opportunity Number: RFA-NS-21-024

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue a small clinical trial to obtain critical information necessary to advance recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain (e.g., Early Feasibility Study).  Clinical studies supported may consist of acute or short-term procedures that are deemed Non-Significant Risk (NSR) by an Institutional Review Board (IRB), or Significant Risk (SR) studies that require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants.  The clinical trial should provide data to answer key questions about the function or final design of a device.  This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval.  The clinical trial is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. Activities supported by this Funding Opportunity include a small clinical trial to answer key questions about the function or final design of a device. As part of the BRAIN Initiative, NIH has initiated a Public-Private Partnership Program (BRAIN PPP) that includes agreements (Memoranda of Understanding, MOU) with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research.  In general it is expected that the devices’ existing safety and utility data will be sufficient to enable new IRB NSR or FDA IDE approval without need for significant additional non-clinical data.  For more information on the BRAIN PPP, see http://braininitiative.nih.gov/BRAIN_PPP/index.htm

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333414

Department of Health and Human Services – National Institutes of Health – Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors Consortium (U01 Clinical Trial Required)

Proposal Due Date: July 14, 2021

Expected Number of Awards:

Estimated Total Program Funding: $5,000,000

Award Ceiling: $875,000

Award Floor:

Funding Opportunity Number: RFA-CA-21-031

Purpose: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) seeks to support exercise and/or medical nutrition intervention research designed to improve cancer treatment-related outcomes for therapies delivered with curative or life-extending intent to cancer survivors. Projects may include either pediatric or adult cancer patient populations and must identify a treatment-related outcome as a primary endpoint and specify a relevant patient-reported secondary outcome(s). Priority will be given to studies with direct clinical relevance and translational potential. Responsive applications will fill a research gap concerning the efficacy of specific exercise and dietary approaches to improve cancer treatment-related outcomes. Information gained should improve behavioral intervention protocols for cancer survivors undergoing cancer treatment and may also generate feasibility information concerning translation into clinical care. Awardees will participate in an Exercise and Nutrition to Improve Cancer Treatment-related Outcomes (ENICTO) in Cancer Survivors Consortium.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333268

Department of Health and Human Services – National Institutes of Health – Coordinating Center for Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors Consortium (U24 Clinical Trial Not Allowed)

Proposal Due Date: July 14, 2021

Expected Number of Awards: 1

Estimated Total Program Funding: $1,000,000

Award Ceiling: $875,000

Award Floor:

Funding Opportunity Number: RFA-CA-21-032

Purpose: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute will support a Coordinating Center (CC) to facilitate coordination across the new Exercise and Medical nutrition Interventions to Improve Cancer Treatment-related Outcomes awardee sites (see U01 awards supported under companion RFA-CA-21-031). This CC will support three to five anticipated cooperative agreement (U01) project sites focused on the conduct of exercise and medical nutrition clinical trials to improve cancer treatment-related outcomes. The CCs primary mission will include collaborative scientific contribution and entail administrative and communication responsibilities. The activities and responsibilities include, but are not limited to, fostering collaboration among transdisciplinary scientific teams across U01 research sites, facilitating identification and collection of common data across U01 sites for use in pilot projects, participating in cross U01 site pilot projects, and leading data analyses, exploring opportunity for novel data collection, examining common research questions across U01 sites, and providing communication and logistical support for annual in-person meetings of the U01 project sites and other cross-site virtual meetings of U01 investigators. The CC will also develop and execute a platform to monitor progress facilitate the evaluation of the initiative across U01 project sites. The awardee will participate in an Exercise and Nutrition to Improve Cancer Treatment-related Outcomes (ENICTO) cooperative agreement consortium.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333249

Department of Health and Human Services – National Institutes of Health – Consortium for Innovative HIV/AIDS Vaccine and Cure Research (UM1 Clinical Trial Not Allowed)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: August 4, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling: $6,000,000

Award Floor:

Funding Opportunity Number: RFA-AI-21-039

Purpose: The purpose of this funding opportunity announcement (FOA) is to support consortia to conduct research toward the prevention and cure of HIV. The Consortium for Innovative HIV Vaccine and Cure Research will establish a collaborative and integrated research program built around two areas of scientific focus: identification of the correlates and the mechanism(s) of protection of preventive vaccine(s) and the use of vaccines or other immune modalities in advancing cure research. Preclinical studies in nonhuman primate (NHP) models will be supported to investigate the mechanism(s), by which efficacious AIDS vaccines protect NHPs from initial infection or establishment of systemic infection, and will incorporate vaccines or other immune interventions into cure strategies in SIV or SHIV-infected NHPs with the objective of eliminating virus reservoirs or establishing elite control of virus replication.  Research findings can be applied to improve HIV vaccines and cure strategies and further advancement toward evaluation in human clinical trials.

https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-039.html

Department of Health and Human Services – National Institutes of Health – NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)

Proposal Due Date: September 5, 2021

Expected Number of Awards: 20

Estimated Total Program Funding:

Award Ceiling: $1,000,000

Award Floor:

Funding Opportunity Number: PAR-21-224

Purpose: This Funding Opportunity Announcement (FOA) encourages small business applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing clinical studies. Diseases chosen for study should be based on the NINDS strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm).

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333352

Department of Health and Human Services – National Institutes of Health – Standardization of C-Peptide and HbA1C Measurements Program (U01 Clinical Trial Not Allowed)

Proposal Due Date: October 20, 2021

Expected Number of Awards: 1

Estimated Total Program Funding: $550,000

Award Ceiling: $350,000

Award Floor:

Funding Opportunity Number: RFA-DK-21-007

Purpose: This Funding Opportunity Announcement (FOA) invites applications for a Central Primary Reference Laboratory (CPRL) to provide support for the harmonization and standardization of laboratory measurements critical for clinical research in type 1 diabetes. The CPRL will provide administrative functions to coordinate harmonization efforts among clinical laboratories and commercial suppliers of reagents and methods and will provide measurements of reference values for C-peptide and HbA1c measurements.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333415

Department of Health and Human Services – National Institutes of Health – Human Milk as a Biological System (R01 Clinical Trial Optional)

Letter of Intent Due Date: October 29, 2021

Proposal Due Date: November 29, 2021

Expected Number of Awards:

Estimated Total Program Funding: $2,000,000

Award Ceiling: $499,999

Award Floor:

Funding Opportunity Number: RFA-HD-22-020

Purpose: This Funding Opportunity Announcement(FOA) invites grant applications that address priority gaps in our understanding of human milk as a biological system and that expand our understanding of the myriad factors influencing the composition and function of human milk using a systems biology approach.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333346

Department of Health and Human Services – National Institutes of Health – Limited Competition: Development and Renovation of Research Space for HIV/AIDS Research at Institutions Serving Underrepresented Populations or Located in Institutional Development Award (IDeA)-eligible States (C06 Clinical Trial Not Allowed)

Letter of Intent Due Date: December 1, 2021

Proposal Due Date: January 6, 2022

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling: $2,000,000

Award Floor:

Funding Opportunity Number: PAR-21-238

Purpose: This Funding Opportunity Announcement (FOA) invites applications from qualified research institutions to seek funds to develop or renovate research facilities that support HIV/AIDS research in areas of basic, translational, clinical, and social and behavioral science research. Targeted are institutions that serve underrepresented and underserved populations or that are in Institutional Development Award (IDeA)-eligible states. Research-intensive institutions are not eligible. The facilities must support research aligned with the NIH-established priorities for HIV/AIDS research. Any request must be justified by current and anticipated future research needs.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333339

Department of Health and Human Services – National Institutes of Health – NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: February 15, 2022

Expected Number of Awards: 20

Estimated Total Program Funding: $20,000,000

Award Ceiling: $700,000

Award Floor:

Funding Opportunity Number: RFA-HL-23-004

Purpose: The purpose of the NHLBI Outstanding Investigator Award (OIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The OIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The OIA will support the research program of NHLBI-funded investigators for up to seven years. The OIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the OIA must be within the scope of the NHLBI mission (https://www.nhlbi.nih.gov/about/mission-statement). It is anticipated that the OIA will: Provide a stable funding environment, thereby improving productivity and facilitating nimble, ambitious, creative research; Accelerate scientific innovation by enabling flexibility in pursuing new research directions as they arise, since PD/PIs will not be bound to specific aims proposed in advance of the studies; Reduce the time researchers spend writing grant applications and managing multiple grant awards, thereby allowing more time to be devoted to conducting research; Facilitate PD/PIs commitment to research through increased stability of funding; and Enable PD/PIs to devote more time and energy to mentoring students and junior scientists and providing scientific service.

https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-004.html

Department of Health and Human Services – National Institutes of Health – NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: February 15, 2022

Expected Number of Awards: 20

Estimated Total Program Funding: $20,000,000

Award Ceiling: $700,000

Award Floor:

Funding Opportunity Number: RFA-HL-23-005

Purpose: The purpose of the NHLBI Emerging Investigator Award (EIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrate their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The EIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards.

The EIA will support the research program of NHLBI-funded investigators for up to seven years. The EIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the EIA must be within the scope of the NHLBI mission.

https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-005.html

Department of Health and Human Services – National Institutes of Health – Support for Small Business Innovation Research (SBIR) to Develop New Technologies for Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (R43/R44 Clinical Trial Not Allowed)

Letter of Intent Due Date: February 9, 2022

Proposal Due Date: March 9, 2022

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-DK-21-011

Purpose: This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of new approaches to create devices/components with enhanced accuracy and less patient burden that will represent real advancements regarding safety and effectiveness of glucose control technologies and their integration into open and closed loop hormone replacement systems.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333378

Department of Health and Human Services – National Institutes of Health – Summer Research Education Experience Program (R25 Clinical Trial Not Allowed)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: March 17, 2022

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-168

Purpose: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this R25 program is to support educational activities that foster a better understanding of biomedical, behavioral and clinical research and its implications.  To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on research experiences for high school or undergraduate students or science teachers during the summer academic break.  The proposed program needs to fit within the mission of the participating IC that the application is being submitted to and should not have a general STEM focus (see below and Table of IC-Specific Information and Points of Contact).

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333438